Inhibitory effects of organophosphate esters on carboxylesterase activity of rat liver microsomes

Yukie Tsugoshi1, Yoko Watanabe1, Yuka Tanikawa1

  • 1Nihon Pharmaceutical University, Komuro 10281, Inamachi, Kitaadachi-gun, Saitama, 362-0806, Japan.

Insights

Organophosphate esters (OPEs) can inhibit carboxylesterase activity, with 2-ethylhexyl diphenyl phosphate (EDPhP) being a potent inhibitor. This study investigates OPEs

Area of Science:

  • Environmental Chemistry
  • Toxicology
  • Biochemistry

Background:

  • Organophosphate esters (OPEs) are widely used as flame retardants and plasticizers.
  • Concerns exist regarding their potential health impacts due to environmental persistence and bioaccumulation.
  • Carboxylesterases are crucial enzymes involved in detoxification and metabolism of various xenobiotics.

Purpose of the Study:

  • To investigate the in vitro inhibitory effects of 13 OPEs and their metabolites on rat liver carboxylesterase activity.
  • To elucidate the structure-activity relationships (SAR) of OPEs concerning carboxylesterase inhibition.
  • To assess the potential human health risks associated with OPE exposure through enzyme inhibition.

Main Methods:

  • In vitro enzyme inhibition assays using rat liver microsomes.
  • Measurement of 4-nitrophenol acetate hydrolase activity to quantify carboxylesterase inhibition.
  • Determination of IC50 values for various OPEs and their metabolites.
  • Lineweaver-Burk plot analysis to determine inhibition kinetics.

Main Results:

  • 2-ethylhexyl diphenyl phosphate (EDPhP) exhibited the most potent inhibition (IC50: 0.03 μM), significantly stronger than bis(4-nitrophenyl) phosphate.
  • Tri-m-cresyl phosphate (TmCP), cresyl diphenyl phosphate (CDPhP), and triphenyl phosphate (TPhP) also showed considerable inhibitory effects.
  • Inhibition kinetics for several OPEs were determined to be non-competitive.
  • Metabolites like diphenyl and monophenyl phosphates displayed weaker inhibition than their parent compound, TPhP.

Conclusions:

  • Certain OPEs, particularly EDPhP, are potent inhibitors of carboxylesterase activity.
  • The study highlights potential toxicological risks of OPEs, necessitating further investigation into human health impacts.
  • Understanding the SAR of OPEs is crucial for designing safer alternatives and assessing environmental risks.

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.4K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
826
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.4K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.7K
Cholinesterases: Distribution and Function01:22

Cholinesterases: Distribution and Function

Cholinesterases are a group of serine hydrolase enzymes that play a crucial role in the breakdown of choline esters. The two primary types of cholinesterases are acetylcholinesterases (AChEs) and butyrylcholinesterase (BuChEs), which differ in their distribution, function, and substrate specificity. AChEs, also known as true cholinesterases, specifically hydrolyze acetylcholine, while BuChEs, often referred to as pseudocholinesterases, can hydrolyze various choline esters, including...
821